Vettermann J, Thomas H, Lischke V, Asskali F
Zentrum der Anästhesiologie und Wiederbelebung, Johann Wolfgang Goethe-Universität Frankfurt.
Anaesthesist. 1996 May;45(5):428-36. doi: 10.1007/s001010050277.
A combination of epidural opioids with local anaesthetics has been used to improve pain relief during labor and to reduce side effects, such as muscle weakness, usually seen when local anaesthetics are used alone. The addition of epidural fentanyl (F) produces highly effective analgesia, the only side effect being mild itching. Initial trials investigated the improvement in analgesia after a single administration of F during first- but not during second-stage labor. Even though pain perception during second-stage labor under epidural analgesia with local anaesthetics can be severe, the addition of opioids was avoided for fear of neonatal or maternal depression. A recent report found maternal and umbilical plasma concentrations following injection of 100 micrograms F to be safe and the investigators speculated that repeated addition of epidural/F to injection of local anaesthetic may prove beneficial for the parturient without exposing the mother or fetus to risk. We therefore studied maternal analgesia, maternal and umbilical plasma levels and associated side effects following repeated addition of 100 micrograms F to bupivacaine epidural analgesia during labor. METHODS. Following institutional and governmental approval 53 parturients were randomly assigned to receive either 8 ml bupivacaine 0.25% + 0.1 mg fentanyl (B + F group; n = 28) or 8 ml bupivacaine 0.25% + 2 ml saline (BUP group; n = 25) in an epidural catheter at L2/3. The same dose was reinjected upon the patients' request regardless of the degree of cervical dilatation. Blood pressure, heart rate, respiratory rate and the incidence of side effects were recorded before and following each epidural injection. Pain relief was determined at each injection and following cord clamping using the visual analogue pain scale (VAS; 0-100 mm). Maternal venous blood samples were collected to measure plasma F concentrations before and 20 and 40 min after each injection and at birth when umbilical venous and arterial blood was obtained. After centrifugation the samples were maintained at -20 degrees C and then analyzed by radioimmunoassay. At delivery, Apgar scores and umbilical venous and arterial blood gas values were determined. RESULTS. Both groups were comparable for age, weight, height, gestational age and parity. A total of 48 epidural injections were evaluated in the B + F group, 43 in the BUP group. No statistically significant group difference was found between the frequency of injections per delivery (B + F: 2.2; BUP: 1.8); regarding the time between the initial and the first top-up dose (B + F: 144 min; BUP: 140 min) or regarding the interval between the last injection and birth (B + F: 94 min; BUP; 90 min). However, the quality of pain relief during labor and particularly at birth was significantly improved by F (mean VAS in B + F group: 6 mm; mean VAS in BUP group: 42 mm). Mild itching was observed in 43% of patients receiving F, moderate shivering in 13% versus 40% in patients not receiving F. At control mean maternal F plasma levels were not zero but 0.25 ng/ml. After the initial injection and following the first and second top-up dose mean maximum maternal F plasma concentrations were 0.54 ng/ml (+/-0.32; +/-SD), 0.88 ng/ml (+/-0.62) and 1.06 ng/ml (+/-0.4) (range 0.18-2.76 ng/ml), respectively. The increase in maternal F concentrations with increasing injection frequency was statistically significant (P < 0.02). Mean umbilical venous and arterial F concentrations at birth were 0.72 ng/ml (+/-1.16) and 0.62 ng/ml (+/-0.52). No significant group differences were found regarding Apgar scores or umbilical blood gas analyses. In one newborn, radioimmunoassay resulted in unexplainably high umbilical F concentrations without any clinical signs of sedation, depressed vigilance and without any sequellae. DISCUSSION. Repeated addition of 100 micrograms F to epidural anaesthesia with bupivacaine significantly improves analgesia and provides pain relief not only during the fir
硬膜外阿片类药物与局部麻醉剂联合使用,可改善分娩期间的疼痛缓解情况,并减少诸如肌肉无力等副作用,而肌肉无力通常是单独使用局部麻醉剂时会出现的情况。添加硬膜外芬太尼(F)可产生高效镇痛效果,唯一的副作用是轻微瘙痒。最初的试验研究了在第一产程而非第二产程单次给予F后镇痛效果的改善情况。尽管在硬膜外使用局部麻醉剂进行镇痛时,第二产程中的疼痛感知可能很强烈,但由于担心新生儿或母体抑制,仍避免添加阿片类药物。最近一份报告发现,注射100微克F后母体和脐血血浆浓度是安全的,研究人员推测,在局部麻醉剂注射中重复添加硬膜外/F可能对产妇有益,且不会使母亲或胎儿面临风险。因此,我们研究了在分娩期间向布比卡因硬膜外镇痛中重复添加100微克F后的母体镇痛效果、母体和脐血血浆水平以及相关副作用。方法:经机构和政府批准后,53名产妇被随机分配,在L2/3硬膜外导管中接受8毫升0.25%布比卡因+0.1毫克芬太尼(B+F组;n=28)或8毫升0.25%布比卡因+2毫升生理盐水(BUP组;n=25)。无论宫颈扩张程度如何,根据患者要求再次注射相同剂量。在每次硬膜外注射前后记录血压、心率、呼吸频率和副作用发生率。在每次注射时以及脐带夹闭后,使用视觉模拟疼痛量表(VAS;0-100毫米)确定疼痛缓解情况。在每次注射前、注射后20和40分钟以及出生时采集母体静脉血样本以测量血浆F浓度,出生时同时采集脐静脉和动脉血。离心后,样本保存在-20℃,然后通过放射免疫测定法进行分析。分娩时,测定阿氏评分以及脐静脉和动脉血气值。结果:两组在年龄、体重、身高、孕周和产次方面具有可比性。B+F组共评估了48次硬膜外注射,BUP组评估了43次。在每次分娩的注射频率(B+F:2.2;BUP:1.8)、首次和第一次追加剂量之间的时间(B+F:144分钟;BUP:140分钟)或最后一次注射与出生之间的间隔(B+F:94分钟;BUP:90分钟)方面,未发现组间有统计学显著差异。然而,F显著改善了分娩期间尤其是出生时的疼痛缓解质量(B+F组平均VAS:6毫米;BUP组平均VAS:42毫米)。接受F的患者中有43%出现轻微瘙痒,13%出现中度寒战,而未接受F的患者中这一比例为40%。对照时母体F血浆水平并非零,而是0.25纳克/毫升。在首次注射后以及第一次和第二次追加剂量后,母体F血浆平均最大浓度分别为0.54纳克/毫升(±0.32;±标准差)、0.88纳克/毫升(±0.62)和1.06纳克/毫升(±0.4)(范围0.18-2.76纳克/毫升)。母体F浓度随注射频率增加而升高具有统计学显著性(P<0.02)。出生时脐静脉和动脉F平均浓度分别为0.72纳克/毫升(±1.16)和0.62纳克/毫升(±0.52)。在阿氏评分或脐血气分析方面未发现组间显著差异。在一名新生儿中,放射免疫测定法得出脐F浓度异常高,但没有任何镇静、警觉性降低的临床体征,也没有任何后遗症。讨论:在布比卡因硬膜外麻醉中重复添加100微克F可显著改善镇痛效果,不仅在第一产程期间提供疼痛缓解,而且在第二产程期间也有效果。在不使母亲或胎儿面临风险的情况下,重复添加F可提高分娩期间的镇痛质量。在我们的研究中,添加F后母体和脐血F浓度均升高,但未发现对新生儿有不良影响。尽管在第二产程中疼痛感知可能很强烈,但重复添加硬膜外F似乎对分娩的产妇是一种安全有效的镇痛方法。